药物相关性颌骨坏死中微生态失衡的研究进展

doi:10.12337/zgkqjxjyzz.2025.05.003

中国口腔医学继续教育杂志 ›› 2025, Vol. 28 ›› Issue (5): 312-321.DOI: 10.12337/zgkqjxjyzz.2025.05.003

药物相关性颌骨坏死中微生态失衡的研究进展

徐冰玥, 鲁涵, 刘柯蓥, 何巍^*

郑州大学第一附属医院·口腔颌面外科

出版日期:2025-09-30 发布日期:2025-09-30
通讯作者: ^* 何巍,联系电话：0371-66862263,电子邮箱：heweizdyfy@163.com,通讯地址：河南省郑州市二七区建设东路 1 号,450000

Advances in the Study of Microecological Dysbiosis in Medication-Related Osteonecrosis of the Jaw

Bingyue Xu, Han Lu, Keying Liu, Wei He^*

Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, P.R. China

Online:2025-09-30 Published:2025-09-30
Contact: Wei He. Tel: 0371-66862263. Email: heweizdyfy@163.com. Address: No. 1 Jianshe East Road, Erqi District, Zhengzhou 450000, Henan Province, P.R. China.

摘要/Abstract

摘要： 药物相关性颌骨坏死（medication-related osteonecrosis of the jaw,MRONJ）是一种因长期使用特定药物引发的颌骨坏死性疾病,主要特征为颌骨暴露、持续疼痛和创口不愈。目前认为其发病机制可能为药物抑制骨重塑、血管生成抑制与微循环障碍、软组织屏障破坏与感染等。口腔菌群失衡与复杂的多菌种混合感染在药物相关性颌骨坏死的发生、进展和慢性化中起到关键作用。本文系统综述了药物相关性颌骨坏死中微生态失衡的发病机制、微生物谱特征、检测技术的应用与进展及微生物相关治疗策略,重点讨论微生物与药物相互作用的复杂性及未来研究方向,以期为临床精准干预提供依据。

Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a necrotic disease of the jaw induced by prolonged use of specific medications, primarily characterized by bone exposure, persistent pain, and non-healing wounds. Current evidence suggests that its pathogenesis may involve inhibition of bone remodeling, suppression of angiogenesis and microcirculation, disruption of the soft tissue barrier, and infection. Dysbiosis of the oral microbiota and complex polymicrobial infections play critical roles in the onset, progression, and chronicity of MRONJ. This review systematically summarizes the pathogenic mechanisms of microecological imbalance, the microbial profiles, detection methods, and microbe-related therapeutic strategies in MRONJ. It focuses on the complexity of microbe-drug interactions and outlines future research directions, aiming to provide a basis for precise clinical interventions.

Key words: medication-related osteonecrosis of the jaw, oral microbiome, biofilm, pathogenic microbiota, precision therapy

徐冰玥, 鲁涵, 刘柯蓥, 何巍. 药物相关性颌骨坏死中微生态失衡的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 312-321.

Bingyue Xu, Han Lu, Keying Liu, Wei He. Advances in the Study of Microecological Dysbiosis in Medication-Related Osteonecrosis of the Jaw[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 312-321.

参考文献

[1] Fusco V, Campisi G, Bedogni A.One changing and challenging scenario: The treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)[J]. Support Care Cancer, 2022, 30(9):7047-7051.
[2] Haviv Y, Geller Z, Mazor S, et al.Pain characteristics in medication-related osteonecrosis of the jaws[J]. Support Care Cancer, 2021, 29(2):1073-1080.
[3] Lee K, Kim K, Kim JY, et al.Mechanisms underlying medication-related osteonecrosis of the jaw[J]. Oral Dis, 2025, 31(4):1073-1083.
[4] Otsuru M, Fujiki Y, Soutome S, et al.Risk factors for dental findings of the development of MRONJ: Investigation of 3734 teeth in cancer patients receiving high-dose antiresorptive agents[J]. J Dent Sci, 2024, 19(1):203-210.
[5] Li Q, Pu Y, Lu H, et al.Porphyromonas, Treponema, and Mogibacterium promote IL8/IFNγ/TNFα-based pro-inflammation in patients with medication-related osteonecrosis of the jaw[J]. J Oral Microbiol, 2020, 13(1):1851112.
[6] Russmueller G, Seemann R, Weiss K, et al.The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection[J]. Sci Rep, 2016, 6:31604.
[7] Du W, Yang M, Kim T, et al.Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice[J]. Int J Oral Sci, 2022, 14(1):16.
[8] Williams DW, Vuong HE, Kim S, et al.Indigenous microbiota protects against inflammation-induced osteonecrosis[J]. J Dent Res, 2020, 99(6):676-684.
[9] Ibrahim N, Apandi NIM, Shuhardi SA, et al.Actinomyces sp. presence in the bone specimens of patients with osteonecrosis of the jaw: The histopathological analysis and clinical implication[J]. Antibiotics (Basel), 2022, 11(8):1067.
[10] Zirk M, Wenzel C, Buller J, et al.Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw[J]. Clin Oral Investig, 2019, 23(5):2143-2151.
[11] Zhang W, Gao L, Ren W, et al.The role of the immune response in the development of medication-related osteonecrosis of the jaw[J]. Front Immunol, 2021, 12:606043.
[12] Katsarelis H, Shah NP, Dhariwal DK, et al.Infection and medication-related osteonecrosis of the jaw[J]. J Dent Res, 2015, 94(4):534-539.
[13] Choi NR, Na HS, Han H, et al.Next-generation sequencing analysis of bacterial species present in the sequestrum of medication-related osteonecrosis of the jaw patients[J]. Arch Oral Biol, 2025;172:106180.
[14] Hallmer F, Bjørnland T, Andersson G, et al.Bacterial diversity in medication-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2017, 123(4):436-444.
[15] Kövér Z, Bán Á, Gajdács M, et al.Role of Actinomyces spp. and related organisms in the development of MRONJ: Clinical evidence based on a case series[J]. Eur J Microbiol Immunol (Bp), 2023, 13(4):125-134.
[16] Panya S, Fliefel R, Probst F, et al.Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ)[J]. J Craniomaxillofac Surg, 2017, 45(3):357-363.
[17] Kim HY, Jung YS, Park W, et al.Can medication-related osteonecrosis of the jaw be attributed to specific microorganisms through oral microbiota analyses? A preliminary study[J]. BMC Oral Health, 2024, 24(1):160.
[18] Bassan Marinho Maciel G, Marinho Maciel R, Linhares Ferrazzo K, et al. Etiopathogenesis of medication-related osteonecrosis of the jaws: A review[J]. J Mol Med (Berl), 2024, 102(3):353-364.
[19] Boff RC, Salum FG, Figueiredo MA, et al.Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws[J]. Arch Oral Biol, 2014, 59(8):790-799.
[20] Scheller EL, Baldwin CM, Kuo S, et al.Bisphosphonates inhibit expression of p63 by oral keratinocytes[J]. J Dent Res, 2011, 90(7): 894-899.
[21] Vozna IV, Pavlov SV, Voznyi OV.The influence of oral antimicrobial peptide content on the quantitative microflora composition in periodontal pockets among residents of a large industrial region[J]. Zaporozhye Medical Journal, 2021, 23(3):388-394.
[22] Jelin-Uhlig S, Weigel M, Ott B, et al.Bisphosphonate-related osteonecrosis of the jaw and oral microbiome: Clinical risk factors, pathophysiology and treatment options[J]. Int J Mol Sci, 2024, 25(15):8053.
[23] Gawęda A, Kałuża A, Wojciechowicz J, et al.Necrosis BRONJ of the mandible, complicated by Actinomyces infection: Case report[J]. J Pre Clin Clin Res, 2018, 12(3):82-86.
[24] Aguirre JI, Castillo EJ, Kimmel DB.Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ)[J]. Bone, 2021, 153:116168.
[25] Yahara H, Hiraki A, Maruoka Y, et al.Shotgun metagenome sequencing identification of a set of genes encoded by Actinomyces associated with medication-related osteonecrosis of the jaw[J]. PLoS One, 2020, 15(11):e0241676.
[26] Wu S, Li F, Tan J, et al.Porphyromonas gingivalis induces bisphosphonate-related osteonecrosis of the femur in mice[J]. Front Cell Infect Microbiol, 2022, 12:886411.
[27] Zhu B, Macleod LC, Newsome E, et al.Aggregatibacter actinomycetemcomitans mediates protection of Porphyromonas gingivalis from Streptococcus sanguinis hydrogen peroxide production in multi-species biofilms[J]. Sci Rep, 2019, 9(1):4944.
[28] Könönen E.Polymicrobial infections with Actinomyces and related organisms: Taxonomy and clinical significance[J]. J Oral Microbiol, 2024, 16(1):2354148.
[29] Yamaguchi-Kuroda Y, Kikuchi Y, Kokubu E, et al.Porphyromonas gingivalis diffusible signaling molecules enhance Fusobacterium nucleatum biofilm formation via gene expression modulation[J]. J Oral Microbiol, 2023, 15(1):2165001.
[30] Sedghizadeh PP, Kumar SK, Gorur A, et al.Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy[J]. J Oral Maxillofac Surg, 2008, 66(4):767-775.
[31] Wang J, Liu C, Cutler J, et al.Microbial- and host immune cell-derived extracellular vesicles in the pathogenesis and therapy of periodontitis: A narrative review[J]. J Periodontal Res, 2024, 59(6):1115-1129.
[32] Peyyala R, Kirakodu SS, Novak KF, et al.Oral epithelial cell responses to multispecies microbial biofilms[J]. J Dent Res, 2013, 92(3):235-240.
[33] Anselmi NK, Vanyo ST, Clark ND, et al.Topology and functional characterization of major outer membrane proteins of Treponema maltophilum and Treponema lecithinolyticum[J]. Mol Oral Microbiol, 2025, 40(1):17-36.
[34] Liu G, Cheng C, Guan X, et al.α-Hemolysin suppresses osteogenesis by inducing lipid rafts accumulation in bone marrow stromal cells[J]. Food Chem Toxicol, 2020, 145:111689.
[35] Sullivan DC, Chapman SW.Bacteria that masquerade as fungi: Actinomycosis/nocardia[J]. Proc Am Thorac Soc, 2010, 7(3):216-221.
[36] Horiuchi A, Kokubu E, Warita T, et al.Synergistic biofilm formation by Parvimonas micra and Fusobacterium nucleatum[J]. Anaerobe, 2020, 62:102100.
[37] Escalante-Herrera A, Chaves M, Villamil JC, et al.In vitro assessment of the antimicrobial activity of tetracycline hydrochloride diluted in three different vehicles against Porphyromonas gingivalis, Prevotella intermedia, and Fusobacterium nucleatum[J]. J Indian Soc Periodontol, 2022, 26(2):104-109.
[38] Kövér Z, Gajdács M, Polgár B, et al.The microbiological background of medication-related osteonecrosis of the jaw (MRONJ): Clinical evidence based on traditional culture and molecular biological detection methods[J]. Antibiotics (Basel), 2025, 14(2):203.
[39] 代静, 陈燕斌, 陈珊, 等. 牙科修复材料苯扎氯铵表面活性剂对5种常见口腔致病菌的体外抑菌效果[J]. 中国组织工程研究, 2018, 22(18):2849-2854.
[40] He L, Wang W, Ma L, et al.Emergence of a clinical Klebsiella pneumoniae harboring an acrAB-tolC in chromosome and carrying the two repetitive tandem core structures for blaKPC-2 and blaCTX-M-65 in a plasmid[J]. Front Cell Infect Microbiol, 2024, 14:1410921.
[41] Badros AZ, Meddeb M, Weikel D, et al.Prospective observational study of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma: Microbiota profiling and cytokine expression[J]. Front Oncol, 2021, 11:704722.
[42] Pushalkar S, Li X, Kurago Z, et al.Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw[J]. Int J Oral Sci, 2014, 6(4):219-226.
[43] Wolff A, Rodloff AC, Vielkind P, et al.Antimicrobial susceptibility of clinical oral isolates of Actinomyces spp[J]. Microorganisms, 2022, 10(1):125.
[44] Zirk M, Kreppel M, Buller J, et al.The impact of surgical intervention and antibiotics on MRONJ stage II and III: A retrospective study[J]. J Craniomaxillofac Surg, 2017, 45(8):1183-1189.
[45] 王铝亚, 张竞心, 林洁. 口腔术后聚维酮碘与氯己定控制感染效果的系统评价分析[J]. 国际口腔医学杂志, 2023, 50(4):438-444.
[46] Ewald F, Wuesthoff F, Koehnke R, et al.Retrospective analysis of bacterial colonization of necrotic bone and antibiotic resistance in 98 patients with medication-related osteonecrosis of the jaw (MRONJ)[J]. Clin Oral Investig, 2021, 25(5):2801-2809.
[47] Kuehn S, Scariot R, Elsalanty M.Medication-related osteonecrosis: Why the jawbone?[J]. Dent J (Basel), 2023, 11(5):109.
[48] Crincoli V, Ballini A, Di Comite M, et al.Microbiological investigation of medication-related osteonecrosis of the jaw: Preliminary results[J]. J Biol Regul Homeost Agents, 2015, 29(4):977-983.
[49] Yamagata K, Uchida F, Kanno N, et al.Chapter: Medication-related osteonecrosis of the jaw. Osteonecrosis[M]. Berlin: Springer, 2017.
[50] Hoefert S.Chapter: Microbiology and antibiotics in the context of medication-related osteonecrosis of the jaw. Medication-Related Osteonecrosis of the Jaws[M]. Berlin: Springer, 2015:121-129.
[51] Brody A, Scheich B, Dobo-Nagy C.Targeted histological evaluation shows high incidence of Actinomyces infection in medication-related osteonecrosis of the jaws[J]. Sci Rep, 2022, 12(1):3406.
[52] Qin M, Zhang X, Ding H, et al.Engineered Probiotic Bio-Heterojunction with Robust Antibiofilm Modality via “Eating” Extracellular Polymeric Substances for Wound Regeneration[J]. Adv Mater, 2024, 36(35):e2402530.
[53] 蔡晨晨, 刘济远, 唐休发, 等. 药物相关性颌骨坏死治疗的研究进展[J]. 中国医学前沿杂志(电子版), 2023, 15(5):37-45.
[54] Goker F, Grecchi E, Grecchi F, et al.Treatment of medication-related osteonecrosis of the jaw (MRONJ): A systematic review[J]. Eur Rev Med Pharmacol Sci, 2021, 25(6):2662-2673.
[55] Heifetz-Li JJ, Abdelsamie S, Campbell CB, et al. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 128(5):491-497.e2.
[56] Hanna R, Miron IC, Dalvi S, et al.A systematic review of laser photobiomodulation dosimetry and treatment protocols in the management of medications-related osteonecrosis of the jaws: a rationalised consensus for future randomised controlled clinical trials[J]. Pharmaceuticals (Basel), 2024, 17(8):1011.
[57] Bennardo F, Barone S, Antonelli A, et al.Autologous platelet concentrates as adjuvant in the surgical management of medication-related osteonecrosis of the jaw[J]. Periodontol 2000, 2025, 97(1):287-307.
[58] Kobayashi E, Takahashi H, Igarashi K, et al.Prognosis of medication-related osteonecrosis of the jaw with surgical treatment[J]. J Hard Tissue Biol, 2022, 31(1):39-46.
[59] Ruggiero SL, Kohn N.Disease stage and mode of therapy are important determinants of treatment outcomes for medication-related osteonecrosis of the jaw[J]. J Oral Maxillofac Surg, 2015, 73(12 Suppl):S94-S100.
[60] Fusco V, Fasciolo A, Gambino A, et al.1794P-Inadequacy of current definition and staging system of medication-related osteonecrosis of jaw (MRONJ) released by AAOMS: A computed tomography study in 151 cancer and myeloma patients[J]. Ann Oncol, 2019, 30(Suppl 5):v731.
[61] 郭玉兴, 张建运, 王佃灿, 等. 药物相关颌骨骨坏死的病理特点及临床治疗策略[J]. 北京大学学报(医学版), 2022, 54(6):1190-1195.

药物相关性颌骨坏死中微生态失衡的研究进展

Advances in the Study of Microecological Dysbiosis in Medication-Related Osteonecrosis of the Jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	丁一辉, 王丹丹, 李晨璐, 王继弘, 田磊, 宗春琳. 特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 297-306.
[2]	何金媛, 孙国文. 药物相关性颌骨坏死的机制及治疗研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 307-311.
[3]	张逸云, 康非吾, 张雪明. 药物相关性颌骨坏死非手术治疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 322-330.
[4]	江晨曦, 孙国文. 药物相关性颌骨坏死临床诊疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 331-336.
[5]	王睿, 孙国文. 3期药物相关性颌骨坏死的手术治疗的回顾性研究[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 345-352.
[6]	何金媛, 孙国文. 斜面导板改善下颌骨药物相关性颌骨坏死的咬合关系1例[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 360-366.
[7]	李娜, 常远, 高宁, 付坤, 蔡菁华, 高振杰, 乔翔鹤, 杨雷雷, 何巍. 药物相关性颌骨坏死的“互联网+”案例教学法的临床应用[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 367-374.